J Michael Wells, Jerry A Krishnan, R Chad Wade, Greg Kinney, Robert A Wise, Enid Neptune, Francesca Polverino, Nicola A Hanania, Matthew Moll, Melanie Königshoff, Divay Chandra, Frank Sciurba, Nathaniel Marchetti, Raúl San José Estépar, Alejandro A Diaz, Karim El-Kersh, Mario Castro, Ying Zhang, Janet T Holbrook, Elizabeth A Sugar, Monica Kraft, Robert J Kaner, Barry Make, Stephen Rennard
{"title":"慢性阻塞性肺病后：肺气肿可以修复吗？","authors":"J Michael Wells, Jerry A Krishnan, R Chad Wade, Greg Kinney, Robert A Wise, Enid Neptune, Francesca Polverino, Nicola A Hanania, Matthew Moll, Melanie Königshoff, Divay Chandra, Frank Sciurba, Nathaniel Marchetti, Raúl San José Estépar, Alejandro A Diaz, Karim El-Kersh, Mario Castro, Ying Zhang, Janet T Holbrook, Elizabeth A Sugar, Monica Kraft, Robert J Kaner, Barry Make, Stephen Rennard","doi":"10.1164/rccm.202408-1602PP","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical and translational observations suggest that repair or new growth of alveolar structures in humans is feasible. The pathways and mechanisms for repairing damaged alveoli have been characterized in <i>in vivo</i> and <i>ex vivo</i> models, and many of these major biological pathways involved in facilitating lung repair have been validated in adult human lung tissue. Improvements in imaging, functional studies, and biomarkers have led to sensitive measures of treatment effects and clinical outcomes that can be used to study emphysema repair in humans with emphysema. Additionally, the development of innovative platform clinical trial designs now allows for the simultaneous testing of multiple drugs and treatment response biomarkers within a heterogenous population, helping to distinguish responders from non-responders. Several approved medications targeting pathways involved in lung repair could be tested to treat emphysema (e.g., all-trans retinoic acid, thiazolidinediones, metformin, non-steroidal anti-inflammatory drugs, and lithium). These advances enable feasible assessment of the scientific premise of lung repair in human emphysema in clinical trials.</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":" ","pages":""},"PeriodicalIF":19.4000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-COPD: Can Emphysema Be Repaired?\",\"authors\":\"J Michael Wells, Jerry A Krishnan, R Chad Wade, Greg Kinney, Robert A Wise, Enid Neptune, Francesca Polverino, Nicola A Hanania, Matthew Moll, Melanie Königshoff, Divay Chandra, Frank Sciurba, Nathaniel Marchetti, Raúl San José Estépar, Alejandro A Diaz, Karim El-Kersh, Mario Castro, Ying Zhang, Janet T Holbrook, Elizabeth A Sugar, Monica Kraft, Robert J Kaner, Barry Make, Stephen Rennard\",\"doi\":\"10.1164/rccm.202408-1602PP\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinical and translational observations suggest that repair or new growth of alveolar structures in humans is feasible. The pathways and mechanisms for repairing damaged alveoli have been characterized in <i>in vivo</i> and <i>ex vivo</i> models, and many of these major biological pathways involved in facilitating lung repair have been validated in adult human lung tissue. Improvements in imaging, functional studies, and biomarkers have led to sensitive measures of treatment effects and clinical outcomes that can be used to study emphysema repair in humans with emphysema. Additionally, the development of innovative platform clinical trial designs now allows for the simultaneous testing of multiple drugs and treatment response biomarkers within a heterogenous population, helping to distinguish responders from non-responders. Several approved medications targeting pathways involved in lung repair could be tested to treat emphysema (e.g., all-trans retinoic acid, thiazolidinediones, metformin, non-steroidal anti-inflammatory drugs, and lithium). These advances enable feasible assessment of the scientific premise of lung repair in human emphysema in clinical trials.</p>\",\"PeriodicalId\":7664,\"journal\":{\"name\":\"American journal of respiratory and critical care medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":19.4000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of respiratory and critical care medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1164/rccm.202408-1602PP\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1164/rccm.202408-1602PP","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Clinical and translational observations suggest that repair or new growth of alveolar structures in humans is feasible. The pathways and mechanisms for repairing damaged alveoli have been characterized in in vivo and ex vivo models, and many of these major biological pathways involved in facilitating lung repair have been validated in adult human lung tissue. Improvements in imaging, functional studies, and biomarkers have led to sensitive measures of treatment effects and clinical outcomes that can be used to study emphysema repair in humans with emphysema. Additionally, the development of innovative platform clinical trial designs now allows for the simultaneous testing of multiple drugs and treatment response biomarkers within a heterogenous population, helping to distinguish responders from non-responders. Several approved medications targeting pathways involved in lung repair could be tested to treat emphysema (e.g., all-trans retinoic acid, thiazolidinediones, metformin, non-steroidal anti-inflammatory drugs, and lithium). These advances enable feasible assessment of the scientific premise of lung repair in human emphysema in clinical trials.
期刊介绍：
The American Journal of Respiratory and Critical Care Medicine focuses on human biology and disease, as well as animal studies that contribute to the understanding of pathophysiology and treatment of diseases that affect the respiratory system and critically ill patients. Papers that are solely or predominantly based in cell and molecular biology are published in the companion journal, the American Journal of Respiratory Cell and Molecular Biology. The Journal also seeks to publish clinical trials and outstanding review articles on areas of interest in several forms. The State-of-the-Art review is a treatise usually covering a broad field that brings bench research to the bedside. Shorter reviews are published as Critical Care Perspectives or Pulmonary Perspectives. These are generally focused on a more limited area and advance a concerted opinion about care for a specific process. Concise Clinical Reviews provide an evidence-based synthesis of the literature pertaining to topics of fundamental importance to the practice of pulmonary, critical care, and sleep medicine. Images providing advances or unusual contributions to the field are published as Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences.
A recent trend and future direction of the Journal has been to include debates of a topical nature on issues of importance in pulmonary and critical care medicine and to the membership of the American Thoracic Society. Other recent changes have included encompassing works from the field of critical care medicine and the extension of the editorial governing of journal policy to colleagues outside of the United States of America. The focus and direction of the Journal is to establish an international forum for state-of-the-art respiratory and critical care medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
